Regulatory report: Q&A – US FDA final guidance on PMTAs and SE reports

On 4th October 2021 the US Food and Drug Administration (FDA) issued two final rules providing additional information on the requirements for Premarket Tobacco Product Applications (PMTAs) and Substantial Equivalence (SE) reports. This report aims to answer questions that may be raised on this topic, in particular taking into account the public comments and responses the FDA has offered.

Request preview

Interested in a preview? Let’s connect

We share insights with professionals we’re in contact with. Let us know a bit about your interest.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*

Interested in a preview? Let’s connect

We share insights with professionals we’re in contact with. Let us know a bit about your interest.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*